Paratyphoid fever primary prevention: Difference between revisions
Hardik Patel (talk | contribs) No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Paratyphoid fever}} | {{Paratyphoid fever}} | ||
{{CMG}} | |||
==Primary Prevention== | |||
== | |||
Typhoid vaccine is recommended for travelers to areas where there is an increased risk of exposure to S.Typhi. | Typhoid vaccine is recommended for travelers to areas where there is an increased risk of exposure to S.Typhi. | ||
===Indications=== | |||
===Indications | |||
The typhoid vaccines do not protect against S. Paratyphi infection. Both typhoid vaccines protect 50%–80% of recipients; travelers should be reminded that typhoid immunization is not 100% effective, and typhoid fever could still occur. Two typhoid vaccines are available in the United States: | The typhoid vaccines do not protect against S. Paratyphi infection. Both typhoid vaccines protect 50%–80% of recipients; travelers should be reminded that typhoid immunization is not 100% effective, and typhoid fever could still occur. Two typhoid vaccines are available in the United States: | ||
*Oral live, [[attenuated]] [[vaccine]]. | *Oral live, [[attenuated]] [[vaccine]]. | ||
*Vi capsular polysaccharide (ViCPS) vaccine for [[intramuscular]] use. | *Vi capsular polysaccharide (ViCPS) vaccine for [[intramuscular]] use. | ||
===Vaccine Administration=== | |||
===Vaccine | |||
The time required for primary vaccination differs for the 2 vaccines, as do the lower age limits. | The time required for primary vaccination differs for the 2 vaccines, as do the lower age limits. | ||
| Line 17: | Line 16: | ||
Primary vaccination with ViCPS consists of one 0.5-mL (25-mg) dose administered intramuscularly. One dose of this vaccine should be given ≥2 weeks before expected exposure. The manufacturer does not recommend the vaccine for infants and children aged <2 years. | Primary vaccination with ViCPS consists of one 0.5-mL (25-mg) dose administered intramuscularly. One dose of this vaccine should be given ≥2 weeks before expected exposure. The manufacturer does not recommend the vaccine for infants and children aged <2 years. | ||
===Vaccine Safety and Adverse Reactions=== | |||
===Vaccine | Adverse reactions to Ty21a vaccine are rare and mainly consist of abdominal discomfort, [[nausea]], [[vomiting]], and [[rash]]. ViCPS vaccine is most often associated with [[headache]] (16%–20%) and injection-site reactions (7%). No information is available on the safety of these vaccines in [[pregnancy]]; it is prudent on theoretical grounds to avoid vaccinating pregnant women. Live, attenuated Ty21a vaccine should not be given to [[immunocompromised]] travelers, including those infected with [[HIV]]. The intramuscular vaccine presents a theoretically safer alternative for this group. The only contraindication to vaccination with ViCPS vaccine is a history of severe local or systemic reactions after a previous dose. Neither of the available vaccines should be given to people with an acute febrile illness. | ||
Adverse reactions to Ty21a vaccine are rare and mainly consist of abdominal discomfort, [[nausea]], [[vomiting]], and [[rash]]. ViCPS vaccine is most often associated with [[headache]] (16%–20%) and injection-site reactions (7%). No information is available on the safety of these vaccines in [[pregnancy]]; it is prudent on theoretical grounds to avoid vaccinating pregnant women. Live, attenuated Ty21a vaccine should not be given to [[immunocompromised]] travelers, including those infected with [[HIV]]. The intramuscular vaccine presents a theoretically safer alternative for this group. | |||
The only contraindication to vaccination with ViCPS vaccine is a history of severe local or systemic reactions after a previous dose. Neither of the available vaccines should be given to people with an acute febrile illness. | |||
===Precautions and Contraindications=== | ===Precautions and Contraindications=== | ||
Theoretical concerns have been raised about the immunogenicity of live, attenuated Ty21a vaccine in people concurrently receiving [[antimicrobials]] (including [[antimalarial]] [[chemoprophylaxis]]), viral vaccines, or [[immune]] [[globulin]]. The growth of the live Ty21a strain is inhibited [[in vitro]] by various [[antibacterial]] agents, and [[vaccination]] with Ty21a should be delayed for >72 hours after the administration of any antibacterial agent. Available data do not suggest that simultaneous administration of oral polio or yellow fever vaccine decreases the immunogenicity of Ty21a. If typhoid vaccination is warranted, it should not be delayed because of administration of viral vaccines. Simultaneous administration of Ty21a and immune globulin does not appear to pose a problem. | Theoretical concerns have been raised about the immunogenicity of live, attenuated Ty21a vaccine in people concurrently receiving [[antimicrobials]] (including [[antimalarial]] [[chemoprophylaxis]]), viral vaccines, or [[immune]] [[globulin]]. The growth of the live Ty21a strain is inhibited [[in vitro]] by various [[antibacterial]] agents, and [[vaccination]] with Ty21a should be delayed for >72 hours after the administration of any antibacterial agent. Available data do not suggest that simultaneous administration of oral polio or yellow fever vaccine decreases the immunogenicity of Ty21a. If typhoid vaccination is warranted, it should not be delayed because of administration of viral vaccines. Simultaneous administration of Ty21a and immune globulin does not appear to pose a problem. | ||
| Line 29: | Line 24: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Needs overview]] | |||
[[ | [[Category:Disease]] | ||
[[ | |||
[[Category:Bacterial diseases]] | [[Category:Bacterial diseases]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 20:47, 6 December 2012
|
Paratyphoid fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Paratyphoid fever primary prevention On the Web |
|
American Roentgen Ray Society Images of Paratyphoid fever primary prevention |
|
Risk calculators and risk factors for Paratyphoid fever primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Primary Prevention
Typhoid vaccine is recommended for travelers to areas where there is an increased risk of exposure to S.Typhi.
Indications
The typhoid vaccines do not protect against S. Paratyphi infection. Both typhoid vaccines protect 50%–80% of recipients; travelers should be reminded that typhoid immunization is not 100% effective, and typhoid fever could still occur. Two typhoid vaccines are available in the United States:
- Oral live, attenuated vaccine.
- Vi capsular polysaccharide (ViCPS) vaccine for intramuscular use.
Vaccine Administration
The time required for primary vaccination differs for the 2 vaccines, as do the lower age limits.
Primary vaccination with oral Ty21a vaccine consists of 4 capsules, 1 taken every other day. The capsules should be kept refrigerated (not frozen), and all 4 doses must be taken to achieve maximum efficacy. Each capsule should be taken with cool liquid no warmer than 98.6°F (37°C), approximately 1 hour before a meal. This regimen should be completed 1 week before potential exposure. The vaccine manufacturer recommends that Ty21a not be administered to infants or children aged <6 years.
Primary vaccination with ViCPS consists of one 0.5-mL (25-mg) dose administered intramuscularly. One dose of this vaccine should be given ≥2 weeks before expected exposure. The manufacturer does not recommend the vaccine for infants and children aged <2 years.
Vaccine Safety and Adverse Reactions
Adverse reactions to Ty21a vaccine are rare and mainly consist of abdominal discomfort, nausea, vomiting, and rash. ViCPS vaccine is most often associated with headache (16%–20%) and injection-site reactions (7%). No information is available on the safety of these vaccines in pregnancy; it is prudent on theoretical grounds to avoid vaccinating pregnant women. Live, attenuated Ty21a vaccine should not be given to immunocompromised travelers, including those infected with HIV. The intramuscular vaccine presents a theoretically safer alternative for this group. The only contraindication to vaccination with ViCPS vaccine is a history of severe local or systemic reactions after a previous dose. Neither of the available vaccines should be given to people with an acute febrile illness.
Precautions and Contraindications
Theoretical concerns have been raised about the immunogenicity of live, attenuated Ty21a vaccine in people concurrently receiving antimicrobials (including antimalarial chemoprophylaxis), viral vaccines, or immune globulin. The growth of the live Ty21a strain is inhibited in vitro by various antibacterial agents, and vaccination with Ty21a should be delayed for >72 hours after the administration of any antibacterial agent. Available data do not suggest that simultaneous administration of oral polio or yellow fever vaccine decreases the immunogenicity of Ty21a. If typhoid vaccination is warranted, it should not be delayed because of administration of viral vaccines. Simultaneous administration of Ty21a and immune globulin does not appear to pose a problem.